Publications hub
Search our publications, laboratory reports, meeting statements, scheduling submissions and scheduling decisions.
We’re still confirming the best location for some of our content. Can't find what you’re looking for? You can also:
- search our Resources
- use the site search bar in the top right of this screen for more results.
Loading...
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
- (-) COVID-19 vaccines (7)
- (-) Listed medicines (7)
- Advisory bodies and committees (362)
- Scheduling (national classification system) (156)
- Prescription medicines (36)
- Advertising (25)
- In Vitro Diagnostic medical devices (IVDs) (24)
- Medicine safety (23)
- Therapeutic goods regulation (20)
- Medical devices safety (13)
- Manufacturing (11)
- Safety (11)
- Complementary medicines (9)
- Non-prescription medicines (9)
- Over the counter (OTC) medicines (8)
- Regulatory compliance (8)
- COVID-19 (6)
- Medicinal cannabis hub (6)
- Registered complementary medicines (6)
- Assessed listed medicines (5)
- Shortages (4)
- Alert/Advisory (3)
- Fees and payments (3)
- Legislation (3)
- Clinical trials (2)
- Compliance and enforcement hub (2)
- Import and export (2)
- Sunscreens (2)
- Artificial Intelligence (AI) (1)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Biological medicines (1)
- Breast implant hub (1)
- Cosmetics (1)
- Disinfectants/Sterilants (1)
- Labelling and packaging (1)
- Metal-on-metal hip replacement implants hub (1)
- Pharmacovigilance (1)
- Prescription opioids hub (1)
- Unique Device Identification (UDI) hub (1)
Search
14 result(s) found, displaying 1 to 14
-
Summary report of residual DNA and endotoxin on COVID-19 mRNA vaccines conducted by TGA Laboratories
TGA laboratory testing reportsThe TGA has conducted a comprehensive evaluation of the residual DNA and endotoxin levels in the two mRNA vaccines supplied in Australia - Comirnaty (Pfizer) and Spikevax (Moderna). -
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 45, held on 4 October 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement for meeting 46, held on 29 November 2023.
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
Meeting statementsAdvisory Committee on Vaccines meeting statement
-
PublicationsThe TGA Pharmacovigilance Inspection Program (PVIP) metrics report for 2021 is now available.
-
PublicationsOutcomes following review of consultation submissions
-
PublicationsThe PVIP aims to strengthen and broaden the TGA's post-market monitoring activities and protect public health
-
PublicationsIn 2019, the TGA conducted 10 pharmacovigilance inspections of Australian medicine sponsors
-
PublicationsThe TGA has conducted a safety review on coumarin in topical listed medicines
-
PublicationsStatistics from inspections conducted from 1 September 2017 to 31 December 2018
-
PublicationsThis Code supersedes the November 1991 edition of the Australian Code of Good Wholesaling Practice for Therapeutic Goods for Human Use.